Postdiagnosis Statin Use and Mortality in Danish Patients With Prostate Cancer

被引:68
|
作者
Larsen, Signe Benzon [1 ]
Dehlendorff, Christian [1 ]
Skriver, Charlotte [1 ]
Dalton, Susanne Oksbjerg [1 ]
Jespersen, Christina Gade [1 ,4 ,5 ]
Borre, Michael [5 ]
Brasso, Klaus [2 ]
Norgaard, Mette [5 ]
Johansen, Christoffer [2 ]
Sorensen, Henrik Toft [5 ]
Hallas, Jesper [6 ]
Friis, Soren [1 ,3 ,5 ]
机构
[1] Danish Canc Soc, Res Ctr, Strandblvd 49, DK-2100 Copenhagen O, Denmark
[2] Copenhagen Univ Hosp, Copenhagen, Denmark
[3] Univ Copenhagen, Copenhagen, Denmark
[4] Viborg Hosp, Viborg, Denmark
[5] Aarhus Univ Hosp, Aarhus, Denmark
[6] Univ Southern Denmark, Odense, Denmark
关键词
RISK; SUBDISTRIBUTION; RECURRENCE; OUTCOMES; QUALITY; OBESITY;
D O I
10.1200/JCO.2016.71.8981
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Increasing evidence indicates that statin use may reduce mortality from prostate cancer. In this work, we examined whether postdiagnosis statin use was associated with reduced cancer-specific mortality or all-cause mortality among patients with prostate cancer in Denmark. Material and Methods From nationwide Danish registries, we identified all patients with incident prostate adenocarcinoma from 1998 to 2011 and retrieved data on tumor and patient characteristics, drug use, and primary treatment. We defined postdiagnosis use (two or more prescriptions) of statins as a time-varying covariate with 1-year lag. Cox proportional hazards regression models used to compute hazard ratios (HRs) for prostate cancer-specific mortality and all-cause mortality through 2013 associated with postdiagnosis statin use. In secondary and sensitivity analyses, we assessed statin use within exposure periods of 1 year or 5 years after prostate cancer diagnosis and evaluated the influence of prediagnosis statin use. Results Among 31,790 patients, 7,365 died of prostate cancer and 11,811 died from other causes during a median follow-up of 2.8 years (interquartile range, 1.3 to 5.1 years) from 1 year after diagnosis. Postdiagnosis statin use was associated with adjusted HRs of 0.83 (95% CI, 0.77 to 0.89) for prostate cancer mortality and 0.81 (95% CI, 0.76 to 0.85) for all-cause mortality. Similar results were observed in 1-year and 5-year sensitivity analyses. No substantial effect measure modification was found with estimated dose or type of statin, clinical stage, Gleason score, or with prediagnosis statin use; however, patients who were diagnosed early in the study period or who underwent radical prostatectomy or endocrine therapy exhibited slightly lower HRs for prostate cancer mortality with postdiagnosis statin use than did those in the overall analyses. Conclusion Postdiagnosis statin use was associated with reduced mortality from prostate cancer; however, it remains to be established whether this association is causal.
引用
收藏
页码:3290 / +
页数:12
相关论文
共 50 条
  • [31] Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer
    Murtola, Teemu J.
    Peltomaa, Antti I.
    Talala, Kirsi
    Maattanen, Liisa
    Taari, Kimmo
    Tammela, Teuvo L. J.
    Auvinen, Anssi
    [J]. EUROPEAN UROLOGY FOCUS, 2017, 3 (2-3): : 212 - 220
  • [32] IMPACT OF STATIN USE ON BIOCHEMICAL RECURRENCE IN PROSTATE CANCER PATIENTS TREATED WITH RADIATION THERAPY
    Lavigne, Danny
    Kaulanjan, Kevin
    Hoeh, Benedikt
    Saad, Fred
    Karakiewicz, Pierre I.
    Flammia, Rocco Simone
    Kluth, Luis Alex
    Mandel, Philipp
    Chun, Felix K. H.
    Taussky, Daniel
    [J]. RADIOTHERAPY AND ONCOLOGY, 2023, 186 : S67 - S68
  • [33] Statin use and mortality risk in Asian patients with prostate cancer receiving androgen deprivation therapy: A population-based cohort study
    Lee, Yan Hiu Athena
    Chan, Jeffrey Shi Kai
    Hui, Jeremy Man Ho
    Tang, Pias
    Liu, Kang
    Dee, Edward Christopher
    Ng, Kenrick
    Tse, Gary
    Ng, Chi Fai
    [J]. CANCER MEDICINE, 2024, 13 (01):
  • [34] Pan-Cancer Analysis of Postdiagnosis Exercise and Mortality
    Lavery, Jessica A.
    Boutros, Paul C.
    Scott, Jessica M.
    Tammela, Tuomas
    Moskowitz, Chaya S.
    Jones, Lee W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (32) : 4982 - +
  • [35] Statin Use, Diabetes Incidence and Mortality in Prediabetic Patients
    Caraballo, Pedro J.
    Castro, Regina
    Yawn, Barbara P.
    Cha, Stephen S.
    Melton, Joseph, III
    [J]. DIABETES, 2011, 60 : A356 - A356
  • [36] Use of Statins and Prostate Cancer Mortality
    Dehlendorff, Christian
    Skriver, Charlotte
    Jespersen, Christina G.
    Borre, Michael
    Norgard, Mette
    Sorensen, Henrik T.
    Brasso, Klaus
    Hallas, Jesper
    Andersen, Klaus K.
    Friis, Soren
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 354 - 354
  • [37] Mortality in Prostate Cancer and Use of Statins
    Tural, Deniz
    Yuce, Deniz
    Kilickap, Saadettin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (21) : 2274 - 2274
  • [38] Statins use and prostate cancer mortality
    Lai, Shih-Wei
    Kuo, Yu-Hung
    Liao, Kuan-Fu
    [J]. EUROPEAN JOURNAL OF CANCER, 2020, 124 : 219 - 220
  • [39] TREATMENT FOR SUBSTANCE USE AND IMPLICATIONS FOR MORTALITY IN ELDERLY PROSTATE CANCER PATIENTS
    Chhatre, S.
    Malkowicz, S. B.
    Metzger, D. S.
    Jayadevappa, R.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : A251 - A251
  • [40] Statin use and risk of prostate cancer: A Danish population-based case-control study, 1997-2010
    Jespersen, Christina G.
    Norgaard, Mette
    Friis, Soren
    Skriver, Charlotte
    Borre, Michael
    [J]. CANCER EPIDEMIOLOGY, 2014, 38 (01) : 42 - 47